• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Supreme Court Temporarily Blocks Oxycontin Maker's Bankruptcy Deal

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

FRIDAY, Aug. 11, 2023 -- A bankruptcy deal that would have shielded the family behind the company that makes Oxycontin from civil lawsuits was temporarily blocked by the U.S. Supreme Court on Thursday. President Joe Biden had asked for a delay in approval of the nationwide settlement, which had been reached with state and local governments.

The settlement with Purdue Pharma would allow the company to become a different entity after emerging from bankruptcy. The Sackler family would contribute $6 billion, but its members would be protected from future lawsuits, the Associated Press reported. The court is asking the parties to show whether bankruptcy law allows for a blanket shield from all litigation by opioid victims.

While the 2nd U.S. Circuit Court of Appeals allowed the reorganization plan, the U.S. Bankruptcy Trustee is opposed to the shield on lawsuits, the AP said. The trustee is being represented by the Justice Department.

"We are confident in the legality of our nearly universally supported Plan of Reorganization, and optimistic that the Supreme Court will agree," Purdue Pharma said in a statement, the AP reported. "Even so, we are disappointed that the U.S. Trustee, despite having no concrete interest in the outcome of this process, has been able to single-handedly delay billions of dollars in value that should be put to use for victim compensation, opioid crisis abatement for communities across the country, and overdose rescue medicines."

A group of parents whose children died from opioid overdoses is asking that the settlement not be accepted, the AP reported. However, other victims were disappointed at the delay. Their attorney, Ed Neiger, praised the court for hearing the case quickly. "They clearly see the urgency of the matter," Neiger said.

Associated Press Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.